Mineralys Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 12, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
During the three months ended March 31, 2025, one of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act)adopted orterminated a contract, instruction, or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act or any non-Rule 10b5-1 trading arrangement (as defined in the SEC’s rules). The material terms of the Rule 10b5-1 trading arrangement are described below:
| Name and Title | Action Taken | Type of Trading Arrangement | Nature of Trading Arrangement | Duration of Trading Arrangement | Number of Securities |
|---|---|---|---|---|---|
| Jon Congleton, President, Chief Executive Officer, and Director | Adoption January 28, 2025 | Trading plan intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c) | Sale of the Company’s common stock pursuant to the terms of the plan | January 1, 2026 to December 31, 2026 | (1) |
(1)The executive’s Rule 10b5-1 trading arrangement provides for the sale of up to 575,270 shares of common stock subject to a restricted stock award granted to Mr. Congleton that vests ratably over time.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.